Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.

Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR). However, the effects of fenofibrate through systemic administration are not as potent as desired due to inefficient drug delivery to the retina. The present study aimed to explore the sustained therapeutic effects of fenofibrate-loaded biodegradable nanoparticles (NP) on both DR and neovascular age-related macular degeneration (AMD). Fenofibrate was successfully encapsulated into poly(lactic- co-glycolic acid) (PLGA) NP (Feno-NP), and Feno-NP were optimized by varying polymer composition to achieve high drug loading and prolonged drug release. The Feno-NP made of PLGA 34 kDa demonstrated a drug content of 6% w/w and a sustained drug release up to 60 days in vitro. Feno-NP (PLGA 34 kDa) was selected for following in vivo studies, and one single intravitreal (IVT) injection of Feno-NP into rat eyes with a 30G fine needle maintained sustained fenofibric acid drug level in the eye for more than 60 days. The efficacy of Feno-NP in DR and neovascular AMD was investigated using streptozotocin (STZ)-induced diabetic rats, laser-induced choroidal neovascularization (CNV) rats, and very low-density lipoprotein receptor knockout ( Vldlr -/-) mice. Therapeutic effects of Feno-NP were evaluated by measuring electroretinogram (ERG), retinal vascular leakage, leukostasis, CNV size, and retinal levels of vascular endothelial growth factor (VEGF) and intracellular adhesion molecule-1 (ICAM-1). In diabetic rats, Feno-NP ameliorated retinal dysfunctions, reduced retinal vascular leakage, inhibited retinal leukostasis, and downregulated the overexpression of VEGF and ICAM-1 at 8 weeks after one IVT injection. In addition, Feno-NP reduced retinal vascular leakage and CNV formation in both CNV rats and Vldlr -/- mice. Moreover, no toxicity of Feno-NP or Blank-NP to retinal structure and function was detected. Feno-NP exhibited good physiochemical characteristics and controlled drug release profile, conferring prolonged beneficial effects on DR and neovascular AMD.

• Publication year

  2019

• Venue

  Molecular Pharmaceutics

• Publication date

  2019-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1021/acs.molpharmaceut.8b01319PMID 30912953PMCID PMC6502649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic implications of nanomedicine for ocular drug delivery.

  2019cited by this paper
• Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis

  2019cited by this paper
• Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.

  2019cited by this paper
• Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy

  2019cited by this paper
• Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation

  2018cited by this paper
• Esterase activity in porcine and albino rabbit ocular tissues

  2018cited by this paper
• Inflammasomes, the eye and anti-inflammasome therapy

  2017cited by this paper
• Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration

  2017cited by this paper
• PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway

  2017cited by this paper
• Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy

  2017cited by this paper
• Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

  2016cited by this paper
• Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo.

  2016cited by this paper
• Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis

  2016cited by this paper
• Spray drying of fenofibrate loaded nanostructured lipid carriers

  2016cited by this paper
• Therapeutic Effects of PPARα on Neuronal Death and Microvascular Impairment

  2015cited by this paper
• Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats.

  2015cited by this paper
• Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation

  2015cited by this paper
• The role of PPAR activation during the systemic response to brain injury

  2015cited by this paper
• Downregulation of Connexin 43 promotes vascular cell loss and excess permeability associated with the development of vascular lesions in the diabetic retina

  2014cited by this paper
• Therapeutic Potential of Topical Fenofibrate Eyedrops in Diabetic Retinopathy and AMD Rat Models

  2014cited by this paper
• Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

  2014cited by this paper
• Continuous Production of Fenofibrate Solid Lipid Nanoparticles by Hot-Melt Extrusion Technology: a Systematic Study Based on a Quality by Design Approach

  2014cited by this paper
• Unexpected low‐dose toxicity of the universal solvent DMSO

  2014cited by this paper
• Preparation of fenofibrate nanoparticles by combined stirred media milling and ultrasonication method.

  2014cited by this paper
• Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus.

  2013cited by this paper
• Fenofibrate-associated nephrotoxicity: a review of current evidence.

  2013cited by this paper
• Nanotechnology Approaches for Ocular Drug Delivery

  2013cited by this paper
• Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

  2013cited by this paper
• Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

  2013cited by this paper
• Current therapeutic approaches in neovascular age-related macular degeneration.

  2013cited by this paper
• Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction

  2013cited by this paper
• Age-related macular degeneration

  2012cited by this paper
• Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

  2012cited by this paper
• Fenofibrate

  2012cited by this paper
• Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy.

  2011cited by this paper
• Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

  2011cited by this paper
• Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats

  2011cited by this paper
• Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor.

  2011cited by this paper
• Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.

  2011cited by this paper
• Fenofibrate

  2011cited by this paper
• Biodegradable polymeric nanoparticles based drug delivery systems.

  2010cited by this paper
• Effects of medical therapies on retinopathy progression in type 2 diabetes.

  2010cited by this paper
• Diabetic retinopathy

  2010cited by this paper
• Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers

  2010cited by this paper
• Biodegradable Implants for Sustained Drug Release in the Eye

  2010cited by this paper
• Antiangiogenic approaches to age-related macular degeneration today.

  2009cited by this paper
• Dimethyl sulphoxide dose–response on rat retinal function

  2009cited by this paper
• Nanoparticle-Mediated Expression of an Angiogenic Inhibitor Ameliorates Ischemia-Induced Retinal Neovascularization and Diabetes-Induced Retinal Vascular Leakage

  2009cited by this paper
• Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke.

  2009cited by this paper
• Short-term complications of intravitreal injections of triamcinolone and bevacizumab

  2008cited by this paper
• Age-related macular degeneration.

  2008cited by this paper
• Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

  2007cited by this paper
• Neurological Recovery-Promoting, Anti-Inflammatory, and Anti-Oxidative Effects Afforded by Fenofibrate, a PPAR Alpha Agonist, in Traumatic Brain Injury

  2007cited by this paper
• Leukocytes in diabetic retinopathy.

  2007cited by this paper
• Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma.

  2007cited by this paper
• Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

  2007cited by this paper
• Challenges and obstacles of ocular pharmacokinetics and drug delivery.

  2006cited by this paper
• Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts

  2006cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• [Age-related macular degeneration].

  2006cited by this paper
• Fenofibrate inhibits angiogenesis in vitro and in vivo

  2003cited by this paper
• Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.

  2002cited by this paper
• [Diabetic retinopathy].

  2001cited by this paper
• Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent

  1999cited by this paper
• Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.

  1999cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper

• Recent advances of age-related macular degeneration (AMD) treatment enabled by nanomaterials

  2026cites this paper
• Recent Trends in the Development and Clinical Translation of Polymer-based Targeted Therapeutic Nanoparticle

  2026cites this paper
• Long-acting fenofibrate-loaded microparticles for treating retinal disorders.

  2025cites this paper
• Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications

  2025cites this paper
• Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance.

  2025cites this paper
• Diabetic Retinopathy in Focus: Update on Treatment Advances, Pharmaceutical Approaches, and New Technologies.

  2025cites this paper
• Core-shell nanotherapeutics for diabetic cataract and retinopathy: current state-of-the-art and translational challenges

  2025cites this paper
• The role of lipid metabolism disorder in the progression and treatment of ocular vascular diseases.

  2025cites this paper
• Modulation of Oxidative Stress in Diabetic Retinopathy: Therapeutic Role of Natural Polyphenols

  2025cites this paper
• Advances in personalized cancer vaccine to nanotechnology innovations.

  2025cites this paper
• Nanomedicines for ocular fibrosis

  2025cites this paper
• Advances in materials science for ocular diseases induced by cardiovascular risk factors

  2025cites this paper
• Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges

  2025cites this paper
• Ocular Drug Delivery: Emerging Approaches and Advances

  2025cites this paper
• Application of Nanomaterials in the Diagnosis and Treatment of Retinal Diseases.

  2025cites this paper
• Revolutionizing drug delivery strategies with probucol to Combat oxidative stress in retinal Degeneration: A comprehensive review.

  2025cites this paper
• Delivery of fenofibrate to ocular tissues using 2-Hydroxypropyl-β-cyclodextrin-Based micelles.

  2025cites this paper
• Procyanidin B2 attenuates microvascular dysfunction in diabetic retinopathy via inhibition of caspase-1/GSDMD mediated pyroptosis.

  2025cites this paper
• Carbohydrate Polymers, Polymeric Nano Drugs, and Nanoparticles Are Used for Advanced Drug Delivery and Therapeutics in Ocular Diseases

  2025cites this paper
• Sustained release of a novel non-fibrate PPARα agonist from microparticles for neuroprotection in murine models of age-related macular degeneration.

  2025cites this paper
• Utilization of Nanoparticles for Treating Age-Related Macular Degeneration

  2025cites this paper
• Nanomaterials in the diagnosis and treatment of ophthalmic diseases

  2024cites this paper
• Polymeric Nanoparticles in Ophthalmology: A Comprehensive Review of Therapeutic Applications

  2024cites this paper
• Nanocarriers Responsive to Light—A Review

  2024cites this paper
• The role of metal nanocarriers, liposomes and chitosan-based nanoparticles in diabetic retinopathy treatment: A review study.

  2024cites this paper
• Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders

  2024cites this paper
• Nanotechnology as a potential treatment for diabetes and its complications: A review.

  2024cites this paper
• Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics

  2024cites this paper
• Nanotechnology in diabetes Management: Revolutionizing treatment and diagnostics

  2024cites this paper
• ROS-Responsive Nanoparticles with Antioxidative Effect for the treatment of Diabetic Retinopathy

  2024cites this paper
• Advanced nanomedicines for the treatment of age-related macular degeneration.

  2024cites this paper
• Advances in Ophthalmic Therapeutic Delivery: A Comprehensive Overview of Present and Future Directions.

  2024cites this paper
• Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment

  2024cites this paper
• Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

  2024cites this paper
• An update on the latest strategies in retinal drug delivery

  2024cites this paper
• Therapeutic Effects of Anti-Inflammatory and Anti-Oxidant Nutritional Supplementation in Retinal Ischemic Diseases

  2024cites this paper
• Retinal ischemic diseases and promising therapeutic molecular targets.

  2024cites this paper
• Polymeric Molecular Envelope Technology for Improved Therapeutics Efficacy: A Review.

  2024cites this paper
• Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials

  2024cites this paper
• Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management

  2024cites this paper
• Multi-physics simulations for investigating the effect of electrode conditions on transscleral ocular iontophoresis for particulate drug delivery into ocular tissues

  2024cites this paper
• Next generation therapeutics for retinal neurodegenerative diseases.

  2024cites this paper
• Role of fenofibrate in multiple sclerosis

  2024cites this paper
• Development of uniform fenofibrate-loaded biodegradable microparticle by membrane emulsification.

  2023cites this paper
• Transient receptor potential channel 6 knockdown prevents high glucose-induced Müller cell pyroptosis.

  2023cites this paper
• Effects of Systemic Drugs on the Development and Progression of Age-Related Macular Degeneration.

  2023cites this paper
• Exploration: Nanoparticles in the Diagnosis and Treatment of Retinal Diseases

  2023cites this paper
• Updates on Biodegradable Formulations for Ocular Drug Delivery

  2023cites this paper
• Polymer- and Lipid-Based Nanocarriers for Ocular Drug Delivery: Current Status and Future Perspectives.

  2023cites this paper
• Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems

  2023influential citation
• Eco-friendly chitosan-based nanostructures in diabetes mellitus therapy: Promising bioplatforms with versatile therapeutic perspectives.

  2023cites this paper
• Maillard Reaction Crosslinked Alginate-Albumin Scaffolds for Enhanced Fenofibrate Delivery to the Retina: A Promising Strategy to Treat RPE-Related Dysfunction

  2023influential citation
• Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

  2023cites this paper
• Emerging trends in nano-based antidiabetic therapeutics: a path to effective diabetes management

  2023cites this paper
• Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation

  2023cites this paper
• Environmental Light Has an Essential Effect on the Disease Expression in a Dominant RPE65 Mutation.

  2023cites this paper
• Nutritional therapy in children with sepsis and septic shock: unresolved questions and the need for an individualized approach

  2023cites this paper
• The modern view of the state of the problem of age-macular degeneration, its connection with genetics

  2023cites this paper
• An insight on ophthalmic drug delivery systems: Focus on polymeric biomaterials-based carriers.

  2023cites this paper
• PATHOGENETICALLY DIRECTED METHOD OF PREVENTION AND TREATMENT OF AGE-MACULAR DEGENERATION

  2023cites this paper
• A review on PLGA particles as a sustained drug-delivery system and its effect on the retina.

  2023cites this paper
• AOPT Abstracts 15th Biennial Scientific Meeting March 4th–7th, 2021 via Virtual Meeting Platform

  2023cites this paper
• Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases.

  2023cites this paper
• Nanomaterials for Targeted Drug Delivery through Skin to Treat Various Diseases: Recent Trends and Future Perspective

  2023cites this paper
• Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy.

  2023cites this paper
• A Trojan horse biomimetic delivery system using mesenchymal stem cells for HIF-1α siRNA-loaded nanoparticles on retinal pigment epithelial cells under hypoxia environment.

  2022cites this paper
• Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process

  2022cites this paper
• Therapeutic roles of PPARα activation in ocular ischemic diseases.

  2022cites this paper
• The novel visual cycle inhibitor (±)-RPE65-61 protects retinal photoreceptors from light-induced degeneration

  2022cites this paper
• Nanomedicine and Healthcare Systems

  2022cites this paper
• Therapeutic Approaches for Age-Related Macular Degeneration

  2022cites this paper
• Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration

  2022cites this paper
• Biodegradable polymeric nanoparticles: An overview

  2022cites this paper
• Penetrating-peptide-mediated non-invasive Axitinib delivery for anti-neovascularisation.

  2022cites this paper
• Structure–Function Relationships in the Rodent Streptozotocin-Induced Model for Diabetic Retinopathy: A Systematic Review

  2022influential citation
• The interplay of environmental luminance and genetics in the retinal dystrophy induced by the dominant RPE65 mutation

  2022cites this paper
• Annexin A1 Promotes Reparative Angiogenesis and Ameliorates Neuronal Injury in Ischemic Retinopathy

  2022cites this paper
• Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies

  2022cites this paper
• Pathogenic Role of Diabetes-Induced Overexpression of Kallistatin in Corneal Wound Healing Deficiency Through Inhibition of Canonical Wnt Signaling

  2022cites this paper
• Consumer Nanoproducts: A Brief Introduction

  2021cites this paper
• Unveiling the Nanotechnology-Based Drug Delivery Systems and Patent Literature for Diabetic Retinopathy

  2021cites this paper
• Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization

  2021cites this paper
• Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration

  2021cites this paper
• Soluble very low‐density lipoprotein receptor (sVLDLR) inhibits fibrosis in neovascular age‐related macular degeneration

  2021cites this paper
• Pyroptosis in the Retinal Neurovascular Unit: New Insights Into Diabetic Retinopathy

  2021cites this paper
• Therapeutic potential of PGC-1α in age-related macular degeneration (AMD) – the involvement of mitochondrial quality control, autophagy, and antioxidant response

  2021cites this paper
• Sirolimus loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential treatment of age-related macular degeneration.

  2021cites this paper
• Therapeutic Approaches Targeting Molecular Signaling Pathways Common to Diabetes and Lung Diseases and Cancer.

  2021cites this paper
• Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift.

  2021cites this paper
• Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration

  2021cites this paper
• A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances

  2021cites this paper
• Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives

  2021cites this paper
• Nanoparticulate Drug Delivery to the Retina.

  2020cites this paper
• Interplay between engineered nanomaterials and microbiota

  2020cites this paper
• Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology

  2020cites this paper
• Recent theranostic paradigms for the management of Age-related macular degeneration.

  2020cites this paper
• Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects

  2020cites this paper
• Pathogenic role of human C-reactive protein in diabetic retinopathy.

  2020cites this paper
• NANOTHERAPIES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE: RECENT ADVANCEMENTS AND CHALLENGES.

  2020cites this paper
• Regulation of Angiogenesis Using Nanomaterial Based Formulations: An Emerging Therapeutic Strategy to Manage Multiple Pathological Conditions

  2020cites this paper